RxDoctor Payments DataLook up a doctor →

Nazish Ahmad, DO

Medical Oncology · Glendale, AZNPI 1609187921

Payments from drug & device makers

$205,463in general payments, 2019–2025

Across 1,041 payments — averaging $197.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$121K
  • E.r. Squibb & Sons, L.L.C.$30K
  • Adaptive Biotechnologies Corporation$17K
  • Pfizer$11K
  • Daiichi Sankyo Inc.$5K
  • Bristol Myers Squibb$3K
  • plus $18K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)191$121,388
E.r. Squibb & Sons, L.L.C.66$30,444
Adaptive Biotechnologies Corporation24$16,547
Pfizer62$10,793
Daiichi Sankyo Inc.29$4,966
Bristol Myers Squibb58$2,532
Novartis63$2,171
Boehringer Ingelheim10$1,941
Johnson & Johnson(2 entities)36$1,559
Exelixis Inc.12$1,461
Merck51$1,003
Genentech USA, Inc.49$990
Amgen31$712
Lilly USA, LLC28$605
Gilead(2 entities)23$541
AbbVie26$501
Incyte Corporation20$432
Sanofi18$423
Abbott3$396
Seagen Inc.17$332
Eisai Inc.14$299
Ipsen Biopharmaceuticals, Inc7$275
EMD Serono, Inc.10$212
GSK12$211
Array Biopharma Inc10$203
Coherus Oncology, Inc.4$199
Blueprint Medicines Corporation8$189
Karyopharm Therapeutics Inc.5$187
Puma Biotechnology, Inc.9$184
Takeda Pharmaceuticals U.S.A., Inc.8$184
Genmab U.S., Inc.6$176
Sumitomo Pharma America, Inc.1$171
Bayer8$169
Tempus AI, Inc2$164
Pharmacosmos Therapeutics Inc.6$154
Inari Medical, Inc.1$151
AVEO Pharmaceuticals, Inc.3$143
Servier Pharmaceuticals LLC6$139
Astellas Pharma US Inc6$136
Springworks Therapeutics, Inc.5$133
Rigel Pharmaceuticals, Inc.5$125
Regeneron Healthcare Solutions, Inc.4$113
Boston Scientific1$106
Stemline Therapeutics Inc.3$91
Pharmacyclics LLC, An Abbvie Company4$91
Mirati Therapeutics, Inc.5$88
Beigene USA, Inc.4$84
Sobi, Inc3$84
Azurity Pharmaceuticals, Inc.4$74
Tesaro, Inc.4$70
AMAG Pharmaceuticals, Inc.4$70
Tersera Therapeutics LLC2$60
Foundation Medicine, Inc.2$54
Progenics Pharmaceuticals, Inc.2$49
Pharming Healthcare, Inc.2$47
Shield Therapeutics Inc2$47
Stryker1$47
Secura Bio, Inc.4$47
CTI Biopharma Corp.2$46
Deciphera Pharmaceuticals Inc.2$46

How this compares

$205,463 in reported general payments places this provider in the 70th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$5,616,247
Medicare patients
484
Services billed
263,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Glendale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →